Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Change in Account Payables (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Change in Account Payables for 9 consecutive years, with -$3.4 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 365.01% to -$3.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7.5 million through Dec 2025, down 623.31% year-over-year, with the annual reading at -$7.5 million for FY2025, 623.31% down from the prior year.
  • Change in Account Payables for Q4 2025 was -$3.4 million at Denali Therapeutics, up from -$4.1 million in the prior quarter.
  • The five-year high for Change in Account Payables was $4.8 million in Q2 2023, with the low at -$4.4 million in Q3 2024.
  • Average Change in Account Payables over 5 years is $116350.0, with a median of $708500.0 recorded in 2021.
  • The sharpest move saw Change in Account Payables skyrocketed 626.11% in 2021, then plummeted 2098.72% in 2022.
  • Over 5 years, Change in Account Payables stood at -$78000.0 in 2021, then tumbled by 2098.72% to -$1.7 million in 2022, then fell by 21.34% to -$2.1 million in 2023, then surged by 161.8% to $1.3 million in 2024, then crashed by 365.01% to -$3.4 million in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$3.4 million, -$4.1 million, and $2.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.